Sold as Mivacron, Mivacron In Dextrose 5% In Plastic Container. Every FDA application for this active ingredient: 1 branded and 2 generic.
As of Nov 15, 2026, FDA lists 3 applications for Mivacurium Chloride (sold as Mivacron, Mivacron In Dextrose 5% In Plastic Container), first approved Jan 22, 1992, with 0 new uses approved and 0 published complete response letters.
| Antagonism of Neostigmine in Continuous Infusion of MivacuriumNeuromuscular Blocking Agents · Beijing Tongren Hospital | Not applicable | Not yet recruiting | Apr 13, 2026 |
| Muscle Relaxant Effect and Safety of Mivacurium Chloride and Succinylcholine for BronchoscopyAnesthesia, Bronchoscopy · Peng Liang | Not applicable | Not yet recruiting | Nov 29, 2024 |
| Jan 22, 1992 | Mivacron, Mivacron In Dextrose 5% In Plastic ContainerNDA 20098 · New molecular entity | Abbvie | 16 | Discontinued |
| Apr 30, 2009 | Mivacurium ChlorideANDA 78562 | Rising | 1 | Discontinued |
| Oct 12, 2021 | Mivacurium ChlorideANDA 209708 | Woodward | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Abbvie